{"id":67409,"date":"2026-05-30T16:41:35","date_gmt":"2026-05-30T11:11:35","guid":{"rendered":"https:\/\/www.equentis.com\/blog\/?p=67409"},"modified":"2026-05-30T16:41:38","modified_gmt":"2026-05-30T11:11:38","slug":"natco-pharma-stock-drops-12-after-q4-profit-declines-34-to-%e2%82%b9268-crore","status":"publish","type":"post","link":"https:\/\/www.equentis.com\/blog\/natco-pharma-stock-drops-12-after-q4-profit-declines-34-to-%e2%82%b9268-crore\/","title":{"rendered":"Natco Pharma Stock Drops 12% After Q4 Profit Declines 34% to \u20b9268 Crore"},"content":{"rendered":"
<\/div>\n

Summary<\/strong><\/h2>\n\n\n\n

Natco Pharma shares witnessed a sharp decline of nearly 12% after the company reported a 34% year-on-year drop in its fourth-quarter profit to \u20b9268 crore. The weak earnings performance appears to be driven by lower revenue contributions from key products, changing market dynamics in export markets, pricing pressure in the generic drug segment, and a challenging operating environment. While the stock market reacted negatively to the earnings miss, investors are also evaluating Natco Pharma’s long-term prospects, including its product pipeline, specialty pharmaceutical portfolio, export opportunities, and future growth initiatives. The development highlights both the near-term challenges and long-term opportunities facing the pharmaceutical company.<\/p>\n\n\n\n

Introduction<\/strong><\/h2>\n\n\n\n

The pharmaceutical sector is often viewed as one of the more resilient segments of the economy. Demand for medicines remains relatively stable regardless of economic conditions, making pharma stocks a popular choice among investors seeking long-term growth opportunities.<\/p>\n\n\n\n

However, even within a defensive sector, quarterly earnings can significantly influence investor sentiment. This was evident when Natco Pharma’s stock price fell sharply following the release of its fourth-quarter results.<\/p>\n\n\n\n

The company reported a 34% decline in net profit to \u20b9268 crore, triggering concerns among investors about revenue growth, profitability trends, and future earnings visibility. The market’s reaction was swift, with the stock dropping around 12% as investors reassessed expectations.<\/p>\n\n\n\n

The results have generated significant discussion among market participants because Natco Pharma has historically been known for its strong product portfolio, export capabilities, and presence in niche pharmaceutical segments.<\/p>\n\n\n\n

Understanding what led to the earnings decline and what it means for investors can provide valuable insight into the company’s future trajectory.<\/p>\n\n\n\n

About Natco Pharma<\/strong><\/h2>\n\n\n\n

Before examining the quarterly performance, it is important to understand Natco Pharma’s business model.<\/p>\n\n\n\n

Natco Pharma is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical products.<\/p>\n\n\n\n

The company has established a presence in several therapeutic segments and is particularly known for:<\/p>\n\n\n\n

    \n
  • Oncology products<\/li>\n\n\n\n
  • Specialty pharmaceuticals<\/li>\n\n\n\n
  • Generic medicines<\/li>\n\n\n\n
  • Active pharmaceutical ingredients (APIs)<\/li>\n\n\n\n
  • Crop health sciences<\/li>\n\n\n\n
  • International pharmaceutical exports<\/li>\n<\/ul>\n\n\n\n

    Over the years, Natco has built a reputation for developing complex generic drugs and niche pharmaceutical products that often carry higher margins than standard generics.<\/p>\n\n\n\n

    This strategy has helped differentiate the company within a highly competitive pharmaceutical industry.<\/p>\n\n\n\n

    What Happened in the Q4 Results?<\/strong><\/h2>\n\n\n\n

    The major trigger for the stock correction was the significant decline in quarterly profit.<\/p>\n\n\n\n

    Profit Falls 34%<\/strong><\/h3>\n\n\n\n

    Natco Pharma reported a net profit of \u20b9268 crore for the fourth quarter, representing a decline of approximately 34% compared to the corresponding period of the previous year.<\/p>\n\n\n\n

    Such a sharp drop naturally attracted investor attention.<\/p>\n\n\n\n

    Market Reaction<\/strong><\/h3>\n\n\n\n

    Stock markets generally react quickly to earnings surprises.<\/p>\n\n\n\n

    When actual results fall below expectations, investors often reassess growth assumptions and valuation multiples.<\/p>\n\n\n\n

    The nearly 12% decline in Natco Pharma’s share price reflects concerns about near-term earnings momentum.<\/p>\n\n\n\n

    Revenue and Margin Pressures<\/strong><\/h3>\n\n\n\n

    While profitability remains positive, the decline suggests pressure on revenue growth, margins, or both.<\/p>\n\n\n\n

    Investors are now focused on understanding whether these challenges are temporary or structural.<\/p>\n\n\n\n

    Why Did Natco Pharma’s Profit Decline?<\/strong><\/h2>\n\n\n\n

    Several factors may have contributed to weaker profitability.<\/p>\n\n\n\n

    Lower Contribution from Key Products<\/strong><\/h3>\n\n\n\n

    Many pharmaceutical companies depend heavily on a few high-value products.<\/p>\n\n\n\n

    If sales of these products decline due to competition, market saturation, or regulatory changes, earnings can be affected significantly.<\/p>\n\n\n\n

    Changes in product mix often influence profitability.<\/p>\n\n\n\n

    Pricing Pressure in Generic Drugs<\/strong><\/h3>\n\n\n\n

    The generic pharmaceutical market remains highly competitive.<\/p>\n\n\n\n

    Price erosion is common, particularly in international markets where multiple manufacturers compete for market share.<\/p>\n\n\n\n

    Lower selling prices can directly impact revenue and margins.<\/p>\n\n\n\n

    Export Market Challenges<\/strong><\/h3>\n\n\n\n

    Natco derives a significant portion of its business from exports.<\/p>\n\n\n\n

    Factors that may affect export performance include:<\/p>\n\n\n\n

      \n
    • Regulatory changes<\/li>\n\n\n\n
    • Currency fluctuations<\/li>\n\n\n\n
    • Competitive pressures<\/li>\n\n\n\n
    • Product approvals<\/li>\n\n\n\n
    • Market access challenges<\/li>\n<\/ul>\n\n\n\n

      Weakness in key export markets can influence quarterly earnings.<\/p>\n\n\n\n

      Higher Operating Costs<\/strong><\/h3>\n\n\n\n

      Increasing expenses related to:<\/p>\n\n\n\n

        \n
      • Research and development<\/li>\n\n\n\n
      • Manufacturing<\/li>\n\n\n\n
      • Compliance<\/li>\n\n\n\n
      • Regulatory requirements<\/li>\n\n\n\n
      • Marketing activities<\/li>\n<\/ul>\n\n\n\n

        can also affect profitability.<\/p>\n\n\n\n

        Understanding the Market’s Reaction<\/strong><\/h2>\n\n\n\n

        A 12% decline in share price may appear severe, but it reflects how investors process new information.<\/p>\n\n\n\n

        Earnings Expectations Matter<\/strong><\/h3>\n\n\n\n

        Stock prices are influenced not only by actual results but also by market expectations.<\/p>\n\n\n\n

        If investors expected stronger growth, weaker earnings can trigger a sharp correction.<\/p>\n\n\n\n

        Future Growth Concerns<\/strong><\/h3>\n\n\n\n

        The market often focuses more on future earnings than past performance.<\/p>\n\n\n\n

        Investors may be questioning whether the profit decline signals a temporary setback or a broader slowdown.<\/p>\n\n\n\n

        Valuation Adjustments<\/strong><\/h3>\n\n\n\n

        Growth-oriented pharmaceutical stocks often trade at premium valuations.<\/p>\n\n\n\n

        When growth slows, valuation multiples may compress.<\/p>\n\n\n\n

        Sentiment-Driven Selling<\/strong><\/h3>\n\n\n\n

        Short-term investors frequently react quickly to disappointing earnings announcements.<\/p>\n\n\n\n

        This can amplify price movements.<\/p>\n\n\n\n

        The Broader Pharmaceutical Industry Context<\/strong><\/h2>\n\n\n\n

        Natco Pharma’s results should be viewed within the context of broader industry trends.<\/p>\n\n\n\n

        Increasing Generic Competition<\/strong><\/h3>\n\n\n\n

        Competition continues intensifying across global generic drug markets.<\/p>\n\n\n\n

        More competitors often lead to lower prices and reduced profitability.<\/p>\n\n\n\n

        Regulatory Scrutiny<\/strong><\/h3>\n\n\n\n

        Pharmaceutical companies operate in highly regulated environments.<\/p>\n\n\n\n

        Regulatory compliance remains both necessary and costly.<\/p>\n\n\n\n

        Focus on Specialty Products<\/strong><\/h3>\n\n\n\n

        Many pharma companies are increasingly focusing on specialty drugs and complex generics to improve margins.<\/p>\n\n\n\n

        Global Healthcare Demand<\/strong><\/h3>\n\n\n\n

        Despite near-term challenges, long-term healthcare demand continues to grow due to:<\/p>\n\n\n\n

          \n
        • Aging populations<\/li>\n\n\n\n
        • Rising healthcare awareness<\/li>\n\n\n\n
        • Increased access to medicines<\/li>\n\n\n\n
        • Expanding healthcare infrastructure<\/li>\n<\/ul>\n\n\n\n

          Natco Pharma’s Key Strengths<\/strong><\/h2>\n\n\n\n

          Despite the recent earnings decline, the company retains several strengths.<\/p>\n\n\n\n

          Expertise in Oncology<\/strong><\/h3>\n\n\n\n

          Cancer treatment remains one of the most important therapeutic areas globally.<\/p>\n\n\n\n

          Natco has developed significant expertise in oncology-focused products.<\/p>\n\n\n\n

          Complex Generic Portfolio<\/strong><\/h3>\n\n\n\n

          Complex generics often face less competition compared to standard generic medicines.<\/p>\n\n\n\n

          This can support better margins.<\/p>\n\n\n\n

          Strong Research Capabilities<\/strong><\/h3>\n\n\n\n

          Research and development remain critical in the pharmaceutical industry.<\/p>\n\n\n\n

          Natco continues investing in product development and regulatory approvals.<\/p>\n\n\n\n

          International Presence<\/strong><\/h3>\n\n\n\n

          The company’s export operations provide access to multiple global markets.<\/p>\n\n\n\n

          Diversification across regions can reduce dependence on a single market.<\/p>\n\n\n\n

          Impact on Investors<\/strong><\/h2>\n\n\n\n

          The latest results create both concerns and opportunities for investors.<\/p>\n\n\n\n

          Short-Term Volatility<\/strong><\/h3>\n\n\n\n

          Earnings disappointments often result in heightened volatility.<\/p>\n\n\n\n

          Investors may continue reacting to management commentary and future guidance.<\/p>\n\n\n\n

          Focus on Long-Term Fundamentals<\/strong><\/h3>\n\n\n\n

          Long-term investors typically evaluate:<\/p>\n\n\n\n

            \n
          • Product pipeline<\/li>\n\n\n\n
          • Market opportunities<\/li>\n\n\n\n
          • Competitive positioning<\/li>\n\n\n\n
          • Balance sheet strength<\/li>\n<\/ul>\n\n\n\n

            rather than focusing solely on a single quarter.<\/p>\n\n\n\n

            Reassessment of Growth Expectations<\/strong><\/h3>\n\n\n\n

            Analysts may revise earnings forecasts following weaker-than-expected results.<\/p>\n\n\n\n

            Valuation Considerations<\/strong><\/h3>\n\n\n\n

            The stock correction could lead some investors to reassess valuation attractiveness.<\/p>\n\n\n\n

            Opportunities for Future Growth<\/strong><\/h2>\n\n\n\n

            Despite current challenges, several opportunities remain available.<\/p>\n\n\n\n

            New Product Launches<\/strong><\/h3>\n\n\n\n

            Future launches could support revenue growth and improve profitability.<\/p>\n\n\n\n

            Specialty Pharmaceuticals<\/strong><\/h3>\n\n\n\n

            Higher-value specialty products continue offering growth potential.<\/p>\n\n\n\n

            Export Market Expansion<\/strong><\/h3>\n\n\n\n

            New geographic markets may provide additional revenue opportunities.<\/p>\n\n\n\n

            Research and Development Pipeline<\/strong><\/h3>\n\n\n\n

            A strong product pipeline can create future earnings drivers.<\/p>\n\n\n\n

            Increasing Healthcare Demand<\/strong><\/h3>\n\n\n\n

            Long-term healthcare consumption trends remain favorable globally.<\/p>\n\n\n\n

            Risks Investors Should Monitor<\/strong><\/h2>\n\n\n\n

            Every investment opportunity comes with risks.<\/p>\n\n\n\n

            Continued Pricing Pressure<\/strong><\/h3>\n\n\n\n

            Persistent price competition could affect margins.<\/p>\n\n\n\n

            Regulatory Risks<\/strong><\/h3>\n\n\n\n

            Approvals, inspections, and compliance requirements remain critical.<\/p>\n\n\n\n

            Product Concentration Risk<\/strong><\/h3>\n\n\n\n

            Heavy reliance on specific products can create earnings volatility.<\/p>\n\n\n\n

            Currency Fluctuations<\/strong><\/h3>\n\n\n\n

            Exchange rate movements may influence export profitability.<\/p>\n\n\n\n

            Competitive Dynamics<\/strong><\/h3>\n\n\n\n

            New market entrants can affect pricing and market share.<\/p>\n\n\n\n

            What Analysts Are Watching Next<\/strong><\/h2>\n\n\n\n

            Following the Q4 results, market participants are focusing on several key areas.<\/p>\n\n\n\n

            Product Pipeline Progress<\/strong><\/h3>\n\n\n\n

            Upcoming launches remain important growth drivers.<\/p>\n\n\n\n

            Export Performance<\/strong><\/h3>\n\n\n\n

            International revenue trends will be closely monitored.<\/p>\n\n\n\n

            Margin Recovery<\/strong><\/h3>\n\n\n\n

            Investors want evidence that profitability can stabilize or improve.<\/p>\n\n\n\n

            Regulatory Developments<\/strong><\/h3>\n\n\n\n

            Approvals and compliance updates may influence future earnings.<\/p>\n\n\n\n

            Management Commentary<\/strong><\/h3>\n\n\n\n

            Guidance regarding future business conditions remains important.<\/p>\n\n\n\n

            How Natco Compares Within the Pharma Sector<\/strong><\/h2>\n\n\n\n

            The Indian pharmaceutical industry includes several large and mid-sized players.<\/p>\n\n\n\n

            Natco differentiates itself through:<\/p>\n\n\n\n

            Focus on Niche Products<\/strong><\/h3>\n\n\n\n

            The company emphasizes complex generics and specialty medicines.<\/p>\n\n\n\n

            Oncology Expertise<\/strong><\/h3>\n\n\n\n

            Its oncology franchise remains a significant competitive advantage.<\/p>\n\n\n\n

            Export-Oriented Strategy<\/strong><\/h3>\n\n\n\n

            Global markets contribute meaningfully to business performance.<\/p>\n\n\n\n

            Research Investments<\/strong><\/h3>\n\n\n\n

            Product development continues supporting long-term growth potential.<\/p>\n\n\n\n

            These strengths may help the company navigate short-term challenges.<\/p>\n\n\n\n

            Long-Term Outlook for Natco Pharma<\/strong><\/h2>\n\n\n\n

            The pharmaceutical industry remains a long-term growth sector.<\/p>\n\n\n\n

            Several structural drivers continue supporting demand.<\/p>\n\n\n\n

            Growing Healthcare Spending<\/strong><\/h3>\n\n\n\n

            Healthcare expenditure continues increasing across many countries.<\/p>\n\n\n\n

            Aging Population<\/strong><\/h3>\n\n\n\n

            Aging demographics contribute to rising medicine consumption.<\/p>\n\n\n\n

            Generic Drug Adoption<\/strong><\/h3>\n\n\n\n

            Governments and healthcare providers continue promoting affordable medicines.<\/p>\n\n\n\n

            Innovation Opportunities<\/strong><\/h3>\n\n\n\n

            Specialty products and complex generics offer growth potential.<\/p>\n\n\n\n

            While quarterly performance may fluctuate, these broader trends continue shaping the industry’s future.<\/p>\n\n\n\n

            What Does This Mean for Shareholders?<\/strong><\/h2>\n\n\n\n

            For shareholders, the latest results serve as a reminder that even established pharmaceutical companies can experience earnings volatility.<\/p>\n\n\n\n

            The key question is whether the current challenges are temporary or indicative of a longer-term slowdown.<\/p>\n\n\n\n

            Investors are likely to focus on:<\/p>\n\n\n\n

              \n
            • Future earnings recovery<\/li>\n\n\n\n
            • Product launches<\/li>\n\n\n\n
            • Export market performance<\/li>\n\n\n\n
            • Margin trends<\/li>\n\n\n\n
            • Competitive positioning<\/li>\n<\/ul>\n\n\n\n

              The answers to these questions will largely determine how the market values Natco Pharma going forward.<\/p>\n\n\n\n

              Conclusion<\/strong><\/h2>\n\n\n\n

              Natco Pharma’s 12% stock decline following a 34% drop in fourth-quarter profit to \u20b9268 crore highlights the importance of earnings performance in shaping investor sentiment. The weaker results appear linked to factors such as pricing pressure, lower contributions from key products, export market challenges, and margin-related concerns.<\/p>\n\n\n\n

              While the market reacted negatively in the short term, the company’s long-term investment case remains tied to its strengths in oncology, specialty pharmaceuticals, complex generics, and international markets. Investors will be closely watching management’s ability to drive future growth through new product launches, research initiatives, and expansion opportunities.<\/p>\n\n\n\n

              As with many pharmaceutical companies, the path forward will depend on balancing innovation, regulatory compliance, operational efficiency, and market competitiveness. Although near-term challenges remain, the broader healthcare industry’s long-term growth trends continue to provide opportunities for companies capable of adapting and executing effectively.<\/p>\n\n\n\n

              Frequently Asked Questions (FAQs)<\/strong><\/h2>\n\n\n\n

              1. Why did Natco Pharma’s stock fall 12%?<\/strong><\/h3>\n\n\n\n

              The stock declined after the company reported a 34% drop in Q4 profit, which disappointed investors.<\/p>\n\n\n\n

              2. What was Natco Pharma’s Q4 profit?<\/strong><\/h3>\n\n\n\n

              The company reported a net profit of \u20b9268 crore for the quarter.<\/p>\n\n\n\n

              3. Why did Natco Pharma’s profit decline?<\/strong><\/h3>\n\n\n\n

              Factors may include lower sales from key products, pricing pressure, export challenges, and higher costs.<\/p>\n\n\n\n

              4. What does Natco Pharma specialize in?<\/strong><\/h3>\n\n\n\n

              Natco Pharma is known for oncology medicines, specialty pharmaceuticals, and complex generics.<\/p>\n\n\n\n

              5. Is the profit decline a long-term concern?<\/strong><\/h3>\n\n\n\n

              Investors are still evaluating whether the weakness is temporary or reflects broader business challenges.<\/p>\n\n\n\n

              6. How important are exports to Natco Pharma?<\/strong><\/h3>\n\n\n\n

              Exports form a significant part of the company’s revenue and growth strategy.<\/p>\n\n\n\n

              7. What opportunities exist for Natco Pharma?<\/strong><\/h3>\n\n\n\n

              New product launches, specialty drugs, export expansion, and healthcare demand growth remain key opportunities.<\/p>\n\n\n\n

              8. What risks should investors monitor?<\/strong><\/h3>\n\n\n\n

              Pricing pressure, regulatory changes, competition, and product concentration risks are important factors.<\/p>\n\n\n\n

              9. How does Natco Pharma differ from other pharma companies?<\/strong><\/h3>\n\n\n\n

              Its focus on oncology products and complex generics provides a degree of differentiation.<\/p>\n\n\n\n

              10. What should investors watch after the Q4 results?<\/strong><\/h3>\n\n\n\n

              Future earnings, product pipeline developments, export performance, regulatory updates, and margin trends will be key indicators.<\/p>\n\n\n\n

              Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This article is for education purposes only and shall not be considered as a recommendation or investment advice by Equentis. We will not be liable for any losses that may occur. Investments in the securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of BASL & certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.<\/p>\n","protected":false},"excerpt":{"rendered":"

              Summary Natco Pharma shares witnessed a sharp decline of nearly 12% after the company reported a 34% year-on-year drop in […]<\/p>\n","protected":false},"author":25,"featured_media":67417,"comment_status":"closed","ping_status":"0","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[948],"tags":[],"class_list":["post-67409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-stock-market-news"],"_links":{"self":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/comments?post=67409"}],"version-history":[{"count":1,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67409\/revisions"}],"predecessor-version":[{"id":67430,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/posts\/67409\/revisions\/67430"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media\/67417"}],"wp:attachment":[{"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/media?parent=67409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/categories?post=67409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.equentis.com\/blog\/wp-json\/wp\/v2\/tags?post=67409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}